<ul>
<li><strong>預計回購約 5 億美元——獲得股東最大批准——計劃於 2026 年 1 月 7 日完成</strong></li>
</ul>
<ul>
<li><strong>資本回購將通過合成股票回購進行——結合了快速直接的資本償還給股東和增強每股收益的反向股票拆分</strong></li>
</ul>
<ul>
<li><strong>QIAGEN 提前兑現承諾，計劃到 2028 年底至少回購 10 億美元，並考慮在 2026 年及以後增加回購方式</strong></li>
</ul>
<p>荷蘭芬洛 --（商業資訊）--QIAGEN N.V.（紐約證券交易所代碼：QGEN；法蘭克福主要標準：QIA）今天宣佈了通過合成股票回購向股東回購約 5 億美元的計劃細節，該回購結合了直接向 QIAGEN 股東償還資本和反向股票拆分。</p>
<p>QIAGEN 在 2025 年 11 月宣佈了回購計劃，此次回購是在 QIAGEN 自 2024 年初以來通過合成股票回購和在 2025 年 6 月實施首次年度股息支付向股東回購約 6.5 億美元之後進行的。</p>
<p>隨着 2026 年 1 月完成此次合成股票回購，QIAGEN 將提前兑現承諾，計劃到 2028 年底至少向股東回購 10 億美元，並考慮在 2026 年及以後採取額外措施以增加回購。</p>
<p>2025 年 6 月的年度股東大會上，股東幾乎一致批准了實施 5 億美元回購的決議。這種方法旨在比傳統的公開市場回購計劃更快、更有效地向股東返還現金。它還通過減少流通股數量來增強每股收益（EPS）。</p>
<p>預計從現有現金儲備的償還將導致已發行股份數量減少約 5%（基於當前股價）。</p>
<p>合成股票回購的條款如下：</p>
<ul>
<li>每 20 股已發行的 QIAGEN 股票將合併為 19 股 QIAGEN 股票，預計將從 2025 年 12 月 18 日的 2.177 億股減少約 1090 萬股。</li>
</ul>
<ul>
<li>在實施合併後，QIAGEN 將向記錄在案的股東償還每股 2.29 美元的資本（由於 QIAGEN 股票的面值以歐元計，資本減少和償還的相關公證文件將以歐元計。然而，支付將以美元進行）。</li>
</ul>
<p>在紐約證券交易所和法蘭克福證券交易所，拆分前股票的最後交易日計劃為 2026 年 1 月 7 日（星期三）。</p>
<p>自 2026 年 1 月 8 日（星期四）起，合併後的 QIAGEN 股票（不包括資本償還的權利）預計將在法蘭克福證券交易所（QIA）和紐約證券交易所（QGEN）以公司的當前股票代碼開始交易。</p>
<p>合併後的 QIAGEN 股票將具有以下新的證券標識符：</p>
<p>ISIN: NL0015002SN0</p>
<p>CUSIP: N72482 156</p>
<p>WKN: A41HBE</p>
<p><strong>結算機制的技術細節</strong></p>
<p>在美國持有 QIAGEN 股票的股東，其持股將根據上述合併比例自動合併，任何零碎股份將計劃出售並將收益存入其賬户，生效日期為 2026 年 1 月 7 日（星期三）東部時間下午 4:00（“生效日期” 及前 ISIN / CUSIP / WKN 的最後交易日）。</p>
<p>資本償還計劃通過存託信託公司在隨後的幾天內向股東的各自經紀賬户進行。生效日期時未結算的市場交易計劃由存託信託公司進行對賬，並按照市場慣例結算。</p>
<p>對於在德國及其他歐洲國家直接或間接通過 Clearstream Banking AG 持有 QIAGEN 股票的股東，這些持股預計將在 2026 年 1 月 7 日（星期三）歐洲時間收盤時通過其銀行、經紀人和保管人進行合併。預計這些股東的資本償還也將在隨後的幾天內進行。任何零碎股份將被出售並存入其賬户。</p>
<p>直接在 Equiniti（前身為美國股票轉讓和信託公司（“AST”））持有 QIAGEN 股票的股東，計劃根據上述合併比例自動合併其持股，並在生效日期生效，通過 Equiniti 持有的登記進行處理，並將資本償還存入公司已知的銀行賬户。</p>
<p>建議股東在有關反向股票拆分和資本償還方面諮詢其銀行或經紀人。</p>
<p>建議股東諮詢當地税務顧問以瞭解其税務狀況。</p>
<p><strong>關於 QIAGEN</strong></p>
<p>QIAGEN N.V.是一家總部位於荷蘭的控股公司，是全球領先的樣本到洞察解決方案提供商，使客户能夠從包含生命基本構件的生物樣本中提取和分析分子信息。我們的樣本技術從血液、組織和其他材料中分離和處理 DNA、RNA 和蛋白質。檢測技術為這些生物分子準備分析，而生物信息學支持複雜數據的解釋，以提供可操作的洞察。自動化解決方案將這些步驟整合到簡化、成本效益高的工作流程中。QIAGEN 在生命科學（學術界、製藥研發和工業應用如法醫）和分子診斷（臨牀醫療）領域為全球超過 500,000 名客户提供服務。截至 2025 年 9 月 30 日，QIAGEN 在 35 個以上的地點僱傭了約 5,700 名員工。有關更多信息，請訪問 https://www.qiagen.com。</p>
<p><strong>前瞻性聲明</strong></p>
<p>本新聞稿中的某些聲明可能構成根據《1933 年美國證券法》第 27A 條和《1934 年美國證券交易法》第 21E 條的前瞻性聲明。這些聲明包括關於 QIAGEN 產品、開發時間表、市場和/或監管批准、財務和運營前景、增長戰略、資本配置戰略、合作關係和運營結果（如預期淨銷售額和調整後稀釋每股收益）、首席執行官過渡計劃、收購 Parse Biosciences 的時間及預期收益，以及合成股票回購的時間及預期收益，均基於當前的預期和假設。然而，這些聲明涉及不確定性和風險。這些風險包括但不限於：在提供運營連續性和持續推進公司戰略的同時，成功管理首席執行官過渡和繼任者搜索的挑戰；管理增長和國際運營的挑戰（包括貨幣波動、關税、税法、監管流程和物流依賴的影響）；運營結果的變動以及為生命科學和臨牀醫療市場客户開發產品的商業化；與客户、供應商或戰略合作伙伴關係的變化；競爭和快速的技術進步；證券市場的發展或變化以及 QIAGEN 股票的交易量和市場價格的波動，以及合成股票回購的成功實施；QIAGEN 成功完成、整合並實現收購 Parse Biosciences 的預期收益的能力，包括由於經濟狀況、客户預算和資金週期等因素導致的 QIAGEN 產品需求波動；獲得和維持我們產品的監管批准；成功將 QIAGEN 的產品適應為綜合解決方案並生產這些產品的困難；以及保護產品差異化以防止競爭對手的影響。市場對新產品的接受度、收購的整合、政府行為、全球或區域經濟發展、自然災害、政治或公共衞生危機以及其他 “不可抗力” 事件可能會帶來額外的風險和不確定性。此外，重組計劃和收購所預期的收益也沒有保證會如預期那樣實現。有關風險和不確定性的更完整討論，請參閲我們最近的 20-F 表格年報和其他提交給或提供給美國證券交易委員會的報告中的 “風險因素” 部分。</p>
<p>來源：QIAGEN N.V.</p>
<p>類別：企業</p>
<p><img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNTEyMTgyMTcxNzJyMQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNTEyMTgyMTcxNzJyMQ"/></p>
<p>在 businesswire.com 查看源版本：https://www.businesswire.com/news/home/20251218217172/en/</p>
<p><strong>聯繫人 QIAGEN：</strong></p>
<p><strong>投資者關係</strong></p>
<p>電子郵件：ir@QIAGEN.com</p>
<p><strong>公共關係</strong></p>
<p>電子郵件：pr@QIAGEN.com</p>
<p>來源：QIAGEN N.V.</p>

快而精醫藥

<p>QIAGEN N.V. 宣佈完成了一項約 5 億美元的合成股票回購，計劃於 2026 年 1 月 7 日進行。此次回購結合了對股東的直接資本返還和反向股票拆分，減少了 5% 的流通股。此舉是 QIAGEN 承諾在 2028 年之前至少向股東返還 10 億美元的一部分。股東在 2025 年 6 月批准了該計劃。新的合併股份將於 2026 年 1 月 8 日開始交易</p>

<ul>
<li><strong>Return of approximately $500 million – maximum approved by shareholders – set to be completed on January 7, 2026</strong></li>
</ul>
<div class="lb-trans"><ul>
<li><strong>預計回購約 5 億美元——獲得股東最大批准——計劃於 2026 年 1 月 7 日完成</strong></li>
</ul>
</div><ul>
<li><strong>Capital return to be conducted through synthetic share repurchase – combines a fast direct capital repayment to shareholders with a reverse stock split that enhances EPS</strong></li>
</ul>
<div class="lb-trans"><ul>
<li><strong>資本回購將通過合成股票回購進行——結合了快速直接的資本償還給股東和增強每股收益的反向股票拆分</strong></li>
</ul>
</div><ul>
<li><strong>QIAGEN delivers well ahead of schedule on its commitment to return at least $1 billion through end-2028, considering additional ways to increase returns in 2026 and beyond</strong></li>
</ul>
<div class="lb-trans"><ul>
<li><strong>QIAGEN 提前兑現承諾，計劃到 2028 年底至少回購 10 億美元，並考慮在 2026 年及以後增加回購方式</strong></li>
</ul>
</div><p>VENLO, Netherlands--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced details for completion of plans to return approximately $500 million to shareholders through a synthetic share repurchase that combines a direct capital repayment to QIAGEN shareholders with a reverse stock split.</p>
<div class="lb-trans"><p>荷蘭芬洛 --（商業資訊）--QIAGEN N.V.（紐約證券交易所代碼：QGEN；法蘭克福主要標準：QIA）今天宣佈了通過合成股票回購向股東回購約 5 億美元的計劃細節，該回購結合了直接向 QIAGEN 股東償還資本和反向股票拆分。</p>
</div><p>QIAGEN announced in November 2025 plans for the repurchase, which comes after QIAGEN has returned about $650 million to shareholders since the start of 2024 through a synthetic share repurchase and the implementation of the first annual dividend payment in June 2025.</p>
<div class="lb-trans"><p>QIAGEN 在 2025 年 11 月宣佈了回購計劃，此次回購是在 QIAGEN 自 2024 年初以來通過合成股票回購和在 2025 年 6 月實施首次年度股息支付向股東回購約 6.5 億美元之後進行的。</p>
</div><p>With the completion of this synthetic share repurchase in January 2026, QIAGEN will have delivered well ahead of schedule on its commitment to return at least $1 billion to shareholders by the end of 2028, and is considering additional measures to increase returns in 2026 and beyond.</p>
<div class="lb-trans"><p>隨着 2026 年 1 月完成此次合成股票回購，QIAGEN 將提前兑現承諾，計劃到 2028 年底至少向股東回購 10 億美元，並考慮在 2026 年及以後採取額外措施以增加回購。</p>
</div><p>Shareholders at the Annual General Meeting in June 2025 gave virtually unanimous approval for resolutions to implement the $500 million repurchase. This approach is designed to return cash to shareholders in a faster and more efficient way than through a traditional open-market repurchase program. It also enhances earnings per share (EPS) through the reduction in outstanding shares.</p>
<div class="lb-trans"><p>2025 年 6 月的年度股東大會上，股東幾乎一致批准了實施 5 億美元回購的決議。這種方法旨在比傳統的公開市場回購計劃更快、更有效地向股東返還現金。它還通過減少流通股數量來增強每股收益（EPS）。</p>
</div><p>The repayment from existing cash reserves is expected to lead to an approximately 5% reduction in the number of issued shares (based on current share price).</p>
<div class="lb-trans"><p>預計從現有現金儲備的償還將導致已發行股份數量減少約 5%（基於當前股價）。</p>
</div><p>The terms of the synthetic share repurchase are as follows:</p>
<div class="lb-trans"><p>合成股票回購的條款如下：</p>
</div><ul>
<li>Every 20 issued QIAGEN shares will be consolidated into 19 QIAGEN shares, leading to a reduction of approximately 10.9 million shares from the level of 217.7 million shares as of December 18, 2025.</li>
</ul>
<div class="lb-trans"><ul>
<li>每 20 股已發行的 QIAGEN 股票將合併為 19 股 QIAGEN 股票，預計將從 2025 年 12 月 18 日的 2.177 億股減少約 1090 萬股。</li>
</ul>
</div><ul>
<li>Following the implementation of the consolidation, QIAGEN will repay capital to shareholders of record $2.29 per pre-consolidation share. (As the par-value of QIAGEN shares is denominated in euros, the amount of the capital decrease and repayment in the respective notarial deeds will be denominated in euros. The payment, however, will be made in U.S. dollars.)</li>
</ul>
<div class="lb-trans"><ul>
<li>在實施合併後，QIAGEN 將向記錄在案的股東償還每股 2.29 美元的資本（由於 QIAGEN 股票的面值以歐元計，資本減少和償還的相關公證文件將以歐元計。然而，支付將以美元進行）。</li>
</ul>
</div><p>The last day of trading of the pre-split shares on the New York Stock Exchange and the Frankfurt Stock Exchange is planned to be Wednesday, January 7, 2026.</p>
<div class="lb-trans"><p>在紐約證券交易所和法蘭克福證券交易所，拆分前股票的最後交易日計劃為 2026 年 1 月 7 日（星期三）。</p>
</div><p>Beginning on Thursday, January 8, 2026, the consolidated QIAGEN shares, excluding the entitlement to the capital repayment, are expected to begin trading on the Frankfurt Stock Exchange (QIA) and on the NYSE (QGEN) under the Company’s current ticker symbols.</p>
<div class="lb-trans"><p>自 2026 年 1 月 8 日（星期四）起，合併後的 QIAGEN 股票（不包括資本償還的權利）預計將在法蘭克福證券交易所（QIA）和紐約證券交易所（QGEN）以公司的當前股票代碼開始交易。</p>
</div><p>The consolidated QIAGEN shares will carry the following new security identifiers:</p>
<div class="lb-trans"><p>合併後的 QIAGEN 股票將具有以下新的證券標識符：</p>
</div><p>ISIN: NL0015002SN0</p>
<div class="lb-trans"><p>ISIN: NL0015002SN0</p>
</div><p>CUSIP: N72482 156</p>
<div class="lb-trans"><p>CUSIP: N72482 156</p>
</div><p>WKN: A41HBE</p>
<div class="lb-trans"><p>WKN: A41HBE</p>
</div><p><strong>Technical details regarding settlement mechanics</strong></p>
<div class="lb-trans"><p><strong>結算機制的技術細節</strong></p>
</div><p>Shareholders holding their QIAGEN shares in brokerage accounts in the United States will have their holdings automatically consolidated in line with the consolidation ratio described above, whereby any fractional shares are planned to be sold and proceeds deposited in their account, effective as of close of business at 4:00 p.m. EST on Wednesday, January 7, 2026 (the “Effective Date” and the last trading day of the prior ISIN / CUSIP / WKN).</p>
<div class="lb-trans"><p>在美國持有 QIAGEN 股票的股東，其持股將根據上述合併比例自動合併，任何零碎股份將計劃出售並將收益存入其賬户，生效日期為 2026 年 1 月 7 日（星期三）東部時間下午 4:00（“生效日期” 及前 ISIN / CUSIP / WKN 的最後交易日）。</p>
</div><p>The capital repayment is planned to be made via Depository Trust Company to the respective brokerage accounts of the shareholders in the subsequent days. Unsettled market trades as of the Effective Date are planned to be reconciled by Depository Trust Company and settled in line with market practice.</p>
<div class="lb-trans"><p>資本償還計劃通過存託信託公司在隨後的幾天內向股東的各自經紀賬户進行。生效日期時未結算的市場交易計劃由存託信託公司進行對賬，並按照市場慣例結算。</p>
</div><p>For shareholders who hold their QIAGEN shares in Germany and elsewhere in Europe directly or indirectly via Clearstream Banking AG, these holdings are expected to be consolidated through their banks, brokers and custodians as of close of business European time on Wednesday, January 7, 2026. The capital repayment for these shareholders is expected to also be made in the subsequent days. Any fractional shares will be sold and deposited in their account.</p>
<div class="lb-trans"><p>對於在德國及其他歐洲國家直接或間接通過 Clearstream Banking AG 持有 QIAGEN 股票的股東，這些持股預計將在 2026 年 1 月 7 日（星期三）歐洲時間收盤時通過其銀行、經紀人和保管人進行合併。預計這些股東的資本償還也將在隨後的幾天內進行。任何零碎股份將被出售並存入其賬户。</p>
</div><p>Shareholders holding their QIAGEN shares in registered form directly at Equiniti (formerly American Stock Transfer and Trust Company (&#34;AST&#34;)) are planned to have their holdings automatically consolidated in line with the consolidation ratio described above by processing in the register held by Equiniti, effective as of the Effective Date, and receive the capital repayment in their bank account known to the Company.</p>
<div class="lb-trans"><p>直接在 Equiniti（前身為美國股票轉讓和信託公司（“AST”））持有 QIAGEN 股票的股東，計劃根據上述合併比例自動合併其持股，並在生效日期生效，通過 Equiniti 持有的登記進行處理，並將資本償還存入公司已知的銀行賬户。</p>
</div><p>Shareholders are advised to consult with their bank or broker with any questions on the reverse stock split and the capital repayment.</p>
<div class="lb-trans"><p>建議股東在有關反向股票拆分和資本償還方面諮詢其銀行或經紀人。</p>
</div><p>Shareholders with questions about their tax status are advised to consult with their local tax advisor.</p>
<div class="lb-trans"><p>建議股東諮詢當地税務顧問以瞭解其税務狀況。</p>
</div><p><strong>About QIAGEN</strong></p>
<div class="lb-trans"><p><strong>關於 QIAGEN</strong></p>
</div><p>QIAGEN N.V., a Netherlands-based holding company, is a global leader in Sample to Insight solutions that enable customers to extract and analyze molecular information from biological samples containing the building blocks of life. Our Sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies prepare these biomolecules for analysis, while bioinformatics support the interpretation of complex data to deliver actionable insights. Automation solutions integrate these steps into streamlined, cost-effective workflows. QIAGEN serves more than 500,000 customers worldwide in the Life Sciences (academia, pharmaceutical R&amp;D and industrial applications such as forensics) and Molecular Diagnostics (clinical healthcare). As of September 30, 2025, QIAGEN employed approximately 5,700 people across over 35 locations. For more information, visit https://www.qiagen.com.</p>
<div class="lb-trans"><p>QIAGEN N.V.是一家總部位於荷蘭的控股公司，是全球領先的樣本到洞察解決方案提供商，使客户能夠從包含生命基本構件的生物樣本中提取和分析分子信息。我們的樣本技術從血液、組織和其他材料中分離和處理 DNA、RNA 和蛋白質。檢測技術為這些生物分子準備分析，而生物信息學支持複雜數據的解釋，以提供可操作的洞察。自動化解決方案將這些步驟整合到簡化、成本效益高的工作流程中。QIAGEN 在生命科學（學術界、製藥研發和工業應用如法醫）和分子診斷（臨牀醫療）領域為全球超過 500,000 名客户提供服務。截至 2025 年 9 月 30 日，QIAGEN 在 35 個以上的地點僱傭了約 5,700 名員工。有關更多信息，請訪問 https://www.qiagen.com。</p>
</div><p><strong>Forward-Looking Statement</strong></p>
<div class="lb-trans"><p><strong>前瞻性聲明</strong></p>
</div><p><em>Certain statements in this press release may constitute forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. These statements, including those regarding QIAGEN’s products, development timelines, marketing and/or regulatory approvals, financial and operational outlook, growth strategies, capital allocation strategies, collaborations and operating results (such as expected net sales and adjusted diluted earnings), the CEO transition plan, the acquisition of Parse Biosciences, including the timing and expected benefits thereof, and the synthetic share repurchase, including the timing and expected befits thereof, are based on current expectations and assumptions. However, they involve uncertainties and risks. These risks include, but are not limited to: challenges in managing a successful CEO transition and successor search while providing operational continuity and continued advancement of company strategy; challenges in managing growth and international operations (including the effects of currency fluctuations, tariffs, tax laws, regulatory processes and logistical dependencies); variability in operating results and the commercial development of products for customers in the Life Sciences and clinical healthcare markets; changes in relationships with customers, suppliers or strategic partners; competition and rapid technological advancement; developments or changes in the securities markets and fluctuations in the trading volume and market price of QIAGEN’s shares and the successful implementation of the synthetic share repurchase; QIAGEN’s ability to successfully close, integrate and achieve the expected benefits of its acquisition of Parse Biosciences, including fluctuating demand for QIAGEN’s products due to factors such as economic conditions, customer budgets and funding cycles; obtaining and maintaining regulatory approvals for our products; difficulties in successfully adapting QIAGEN's products into integrated solutions and producing these products; and protecting product differentiation from competitors. Additional risks and uncertainties may arise from market acceptance of new products, integration of acquisitions, governmental actions, global or regional economic developments, natural disasters, political or public health crises, and other “force majeure” events. There is also no guarantee that anticipated benefits from restructuring programs and acquisitions will materialize as expected. For a more complete discussion of risks and uncertainties, please refer to the “Risk Factors” section in our most recent Annual Report on Form 20-F and other reports filed with or furnished to the U.S. Securities and Exchange Commission.</em></p>
<div class="lb-trans"><p>本新聞稿中的某些聲明可能構成根據《1933 年美國證券法》第 27A 條和《1934 年美國證券交易法》第 21E 條的前瞻性聲明。這些聲明包括關於 QIAGEN 產品、開發時間表、市場和/或監管批准、財務和運營前景、增長戰略、資本配置戰略、合作關係和運營結果（如預期淨銷售額和調整後稀釋每股收益）、首席執行官過渡計劃、收購 Parse Biosciences 的時間及預期收益，以及合成股票回購的時間及預期收益，均基於當前的預期和假設。然而，這些聲明涉及不確定性和風險。這些風險包括但不限於：在提供運營連續性和持續推進公司戰略的同時，成功管理首席執行官過渡和繼任者搜索的挑戰；管理增長和國際運營的挑戰（包括貨幣波動、關税、税法、監管流程和物流依賴的影響）；運營結果的變動以及為生命科學和臨牀醫療市場客户開發產品的商業化；與客户、供應商或戰略合作伙伴關係的變化；競爭和快速的技術進步；證券市場的發展或變化以及 QIAGEN 股票的交易量和市場價格的波動，以及合成股票回購的成功實施；QIAGEN 成功完成、整合並實現收購 Parse Biosciences 的預期收益的能力，包括由於經濟狀況、客户預算和資金週期等因素導致的 QIAGEN 產品需求波動；獲得和維持我們產品的監管批准；成功將 QIAGEN 的產品適應為綜合解決方案並生產這些產品的困難；以及保護產品差異化以防止競爭對手的影響。市場對新產品的接受度、收購的整合、政府行為、全球或區域經濟發展、自然災害、政治或公共衞生危機以及其他 “不可抗力” 事件可能會帶來額外的風險和不確定性。此外，重組計劃和收購所預期的收益也沒有保證會如預期那樣實現。有關風險和不確定性的更完整討論，請參閲我們最近的 20-F 表格年報和其他提交給或提供給美國證券交易委員會的報告中的 “風險因素” 部分。</p>
</div><p>Source: QIAGEN N.V.</p>
<div class="lb-trans"><p>來源：QIAGEN N.V.</p>
</div><p>Category: Corporate</p>
<div class="lb-trans"><p>類別：企業</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNTEyMTgyMTcxNzJyMQ" alt="" original-src="https://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20251218217172r1&amp;sid=acqr8&amp;distro=nx&amp;lang=en"/></p>
<p>View source version on businesswire.com: https://www.businesswire.com/news/home/20251218217172/en/</p>
<div class="lb-trans"><p>在 businesswire.com 查看源版本：https://www.businesswire.com/news/home/20251218217172/en/</p>
</div><p><strong>Contacts QIAGEN:</strong></p>
<div class="lb-trans"><p><strong>聯繫人 QIAGEN：</strong></p>
</div><p><strong>I</strong> <strong>nvestor Relations</strong></p>
<div class="lb-trans"><p><strong>投資者關係</strong></p>
</div><p>e-mail: ir@QIAGEN.com</p>
<div class="lb-trans"><p>電子郵件：ir@QIAGEN.com</p>
</div><p><strong>Public Relations</strong></p>
<div class="lb-trans"><p><strong>公共關係</strong></p>
</div><p>e-mail: pr@QIAGEN.com</p>
<div class="lb-trans"><p>電子郵件：pr@QIAGEN.com</p>
</div><p>Source: QIAGEN N.V.</p>
<div class="lb-trans"><p>來源：QIAGEN N.V.</p>
</div>

快而精醫藥宣佈完成合成股票回購，金額最高約為 5 億美元 | QGEN 股票新聞